TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CLOTRIMAZOLE

CLOTRIMAZOLE
Infectious Disease Approved 1993-07-16
Jump to: Indications Approvals Trials Competitors Similar Safety Patents
13
Indications
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1993-07-16
Routes
TOPICAL, ORAL, VAGINAL
Dosage Forms
CREAM, SOLUTION, TROCHE/LOZENGE

Companies

GLENMARK PHARMS SUN PHARMA CANADA FOUGERA PHARMS NOVITIUM PHARMA TP ANDA HOLDINGS SCIEGEN PHARMS Hikma P AND L Teva THINQ PHARM-CRO PVT PADAGIS US
Active Ingredient: CLOTRIMAZOLE

CLOTRIMAZOLE Approval History

Loading approval history...

What CLOTRIMAZOLE Treats

5 indications

CLOTRIMAZOLE is approved for 5 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Candidiasis
  • Tinea Versicolor
  • Tinea Pedis
  • Tinea Cruris
  • Tinea Corporis
Source: FDA Label

Drugs Similar to CLOTRIMAZOLE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

EXELDERM
SULCONAZOLE NITRATE
4 shared
JOURNEY
Shared indications:
Tinea PedisTinea CrurisTinea Corporis +1 more
OXICONAZOLE NITRATE
OXICONAZOLE NITRATE
4 shared
SUN PHARMA CANADA
Shared indications:
Tinea PedisTinea CrurisTinea Corporis +1 more
CLOTIC
CLOTRIMAZOLE
3 shared
CARWIN PHARM ASSOC
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE
3 shared
FOUGERA PHARMS
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
FULVICIN P/G
GRISEOFULVIN, ULTRAMICROSIZE
3 shared
CHARTWELL RX
Shared indications:
Tinea CorporisTinea PedisTinea Cruris
FULVICIN P/G 165
GRISEOFULVIN, ULTRAMICROSIZE
3 shared
CHARTWELL RX
Shared indications:
Tinea CorporisTinea PedisTinea Cruris
FULVICIN-U/F
GRISEOFULVIN, MICROSIZE
3 shared
CHARTWELL RX
Shared indications:
Tinea CorporisTinea PedisTinea Cruris
GRISEOFULVIN
GRISEOFULVIN, MICROSIZE
3 shared
Novartis
Shared indications:
Tinea corporisTinea crurisTinea pedis
LUZU
LULICONAZOLE
3 shared
BAUSCH
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
OXISTAT
OXICONAZOLE NITRATE
3 shared
FOUGERA PHARMS
Shared indications:
Tinea PedisTinea CrurisTinea Corporis
SCLEROSOL
TALC
2 shared
SCIARRA LABS
Shared indications:
Tinea PedisTinea Corporis
STERITALC
TALC
2 shared
NOVATECH SA
Shared indications:
Tinea PedisTinea Corporis
TALC
TALC
2 shared
SCIARRA LABS
Shared indications:
Tinea PedisTinea Corporis
ANCOBON
FLUCYTOSINE
1 shared
BAUSCH
Shared indications:
Candidiasis
DIFLUCAN
FLUCONAZOLE
1 shared
Pfizer
Shared indications:
Candidiasis
ECOZA
ECONAZOLE NITRATE
1 shared
RESILIA PHARMS
Shared indications:
Tinea Pedis
ERTACZO
SERTACONAZOLE NITRATE
1 shared
LACER PHARMA
Shared indications:
Tinea Pedis
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%
FLUCONAZOLE
1 shared
Fresenius Kabi
Shared indications:
Candidiasis
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
FLUCONAZOLE
1 shared
WOODWARD
Shared indications:
Candidiasis
FLUCYTOSINE
FLUCYTOSINE
1 shared
SIGMAPHARM LABS LLC
Shared indications:
Candidiasis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLOTRIMAZOLE FDA Label Details

Pro

Indications & Usage

INDICATIONS & USAGE Prescription Clotrimazole Topical Solution product is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . This formulation is also available as a nonprescription product which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes, Epidermophyton fluoccosum, and Microsporum canis .

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA090219 → Label: DailyMed → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.